Charlotte E. Ariyan, Ph.D.
Affiliations: | 2003 | Yale University, New Haven, CT |
Area:
Immunology, Medicine and SurgeryGoogle:
"Charlotte Ariyan"Parents
Sign in to add mentor| Kim Bottomly | grad student | 2003 | Yale | |
| (Strategies to improve islet cell transplantation.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Pavlick AC, Ariyan CE, Buchbinder EI, et al. (2023) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. Journal For Immunotherapy of Cancer. 11 |
| Hu Y, Briggs A, Gennarelli RL, et al. (2020) Sentinel Lymph Node Biopsy for T1b Melanoma: Balancing Prognostic Value and Cost. Annals of Surgical Oncology |
| Bartlett EK, Lee AY, Spanheimer PM, et al. (2020) Nodal and systemic recurrence following observation of a positive sentinel lymph node in melanoma. The British Journal of Surgery |
| Kelly CM, Antonescu CR, Bowler T, et al. (2020) Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. Jama Oncology |
| Bello DM, Panageas KS, Hollmann T, et al. (2019) Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Annals of Surgical Oncology |
| Bartlett EK, Flynn JR, Panageas KS, et al. (2019) High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. Cancer |
| Perez MC, Zager JS, Amatruda T, et al. (2019) Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1). Melanoma Management. 6: MMT19 |
| Amaria RN, Menzies AM, Burton EM, et al. (2019) Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. The Lancet. Oncology. 20: e378-e389 |
| Navarrete-Dechent C, Aleissa S, Ariyan C, et al. (2019) Comment on "Comparison of surgical margins for lentigo maligna versus melanoma in situ". Journal of the American Academy of Dermatology. 81 |
| Samstein RM, Lee CH, Shoushtari AN, et al. (2019) Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics |